West Paces Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.83K | Buy |
+36
| New | +$6.77K | ﹤0.01% | 423 |
|
|
2025
Q2 | – | Sell |
-63
| Closed | -$9.19K | – | 232 |
|
|
2025
Q1 | $9.19K | Hold |
63
| – | – | ﹤0.01% | 354 |
|
|
2024
Q4 | $8.19K | Hold |
63
| – | – | ﹤0.01% | 360 |
|
|
2024
Q3 | $9.74K | Hold |
63
| – | – | ﹤0.01% | 359 |
|
|
2024
Q2 | $9.75K | Hold |
63
| – | – | ﹤0.01% | 354 |
|
|
2024
Q1 | $8.47K | Sell |
63
-102
| -62% | -$13.5K | ﹤0.01% | 375 |
|
|
2023
Q4 | $22.2K | Hold |
165
| – | – | 0.01% | 293 |
|
|
2023
Q3 | $22.3K | Hold |
165
| – | – | 0.01% | 286 |
|
|
2023
Q2 | $23.6K | Sell |
165
-75
| -31% | -$11K | 0.01% | 291 |
|
|
2023
Q1 | $33.3K | Buy |
+240
| New | +$32.3K | 0.01% | 254 |
|
|
2022
Q2 | – | Sell |
-513
| Closed | -$68K | – | 582 |
|
|
2022
Q1 | $68K | Hold |
513
| – | – | 0.02% | 207 |
|
|
2021
Q4 | $59.7K | Hold |
513
| – | – | 0.02% | 216 |
|
|
2021
Q3 | $61.6K | Hold |
513
| – | – | 0.02% | 195 |
|
|
2021
Q2 | $61.4K | Hold |
513
| – | – | 0.02% | 189 |
|
|
2021
Q1 | $51K | Hold |
513
| – | – | 0.02% | 187 |
|
|
2020
Q4 | $51.2K | Hold |
513
| – | – | 0.02% | 185 |
|
|
2020
Q3 | $56.2K | Hold |
513
| – | – | 0.03% | 169 |
|
|
2020
Q2 | $54.2K | Hold |
513
| – | – | 0.03% | 168 |
|
|
2020
Q1 | $45.8K | Hold |
513
| – | – | 0.03% | 172 |
|
|
2019
Q4 | $51.1K | Hold |
513
| – | – | 0.03% | 189 |
|
|
2019
Q3 | $45.7K | Hold |
513
| – | – | 0.03% | 187 |
|
|
2019
Q2 | $42.3K | Sell |
513
-23
| -4% | -$1.8K | 0.03% | 185 |
|
|
2019
Q1 | $43.3K | Hold |
536
| – | – | 0.03% | 187 |
|
|
2018
Q4 | $40.7K | Hold |
536
| – | – | 0.03% | 188 |
|
|
2018
Q3 | $42.4K | Hold |
536
| – | – | 0.03% | 195 |
|
|
2018
Q2 | $37.6K | Buy |
536
+23
| +4% | +$1.66K | 0.03% | 198 |
|
|
2018
Q1 | $35.8K | Hold |
513
| – | – | 0.03% | 194 |
|
|
2017
Q4 | $35.6K | Hold |
513
| – | – | 0.03% | 209 |
|
|
2017
Q3 | $34.7K | Hold |
513
| – | – | 0.03% | 208 |
|
|
2017
Q2 | $34.9K | Sell |
513
-355
| -41% | -$23.2K | 0.03% | 203 |
|
|
2017
Q1 | $54K | Sell |
868
-185
| -18% | -$10.8K | 0.04% | 166 |
|
|
2016
Q4 | $57.5K | Buy |
+1,053
| New | +$59.8K | 0.05% | 172 |
|
Other funds holding AZN
EP
IA
West Paces Advisors's AZN Position: Q2 2026 in Review
West Paces Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 36 shares worth $6.83K. The stake represents ﹤0.01% of the portfolio and ranks #423 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in AZN as recently as Q1 2025.
West Paces Advisors first reported a position in AZN in Q4 2016 and has held it in 32 quarters since. The position peaked at $68K in Q1 2022. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- West Paces Advisors held 36 shares of AstraZeneca worth $6.83K as of Q2 2026.
- AstraZeneca was a new West Paces Advisors position in Q2 2026.
- AstraZeneca made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #423 holding.
- West Paces Advisors first reported a position in AstraZeneca in Q4 2016 and has held it in 32 quarters since.
- West Paces Advisors's AstraZeneca position peaked at $68K in Q1 2022.
- 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.